This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maitland, M. L. Articles by Ratain, M. J. Search for Related Content PubMed PubMed Citation Articles by Maitland, M. L. Articles by Ratain, M. J. Social Bookmarking                            What's this?

Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics

Michael L. Maitland, Anna DiRienzo, Mark J. Ratain

From the Section of Hematology/Oncology, Department of Medicine; Committee on Clinical Pharmacology and Pharmacogenomics; Department of Human Genetics; Cancer Research Center; University of Chicago, Chicago, IL

Address reprint requests to Mark Ratain, MD, University of Chicago Medical Center, Clinical Pharmacology & Pharmacogenomics, 5841 S Maryland Ave, MC2115, Chicago, IL 60637-1470; e-mail: mratain{at}medicine.bsd.uchicago.edu

Increasingly, investigators are recognizing differences in tumor biology, drug metabolism, toxicity, and therapeutic response among different patient populations receiving anticancer agents. These observations provide exciting opportunities to identify the factors most important for predicting individual variability in pharmacologically relevant phenotypes and consequently for personalizing the delivery of cancer therapy. Although pharmacogenomic differences may explain some of these disparities, rigorous investigation of both genetic and nongenetic differences is important to identify the variables most important for optimal selection and dosing of treatment for an individual patient. For example, pharmacogenetic tests currently used in cancer therapy, such as genotyping UGT1A1 to reduce the incidence of severe toxicity of irinotecan and sequencing epidermal growth factor receptor from tumors to identify somatic mutations conferring sensitivity to tyrosine kinase inhibitors, were developed without initial identification of interpopulation differences. Although interpopulation variability in toxicity and efficacy of these agents has been observed, the basis for these population differences remains only partially explained. Here, we review concepts of human population genetics to inform interpretations of disparate drug effects of cancer therapy across patient populations. Understanding these principles will help investigators better design clinical trials to identify the variables most relevant to subsequent individualization of a cancer therapy.

Supported in part by the Pharmacogenetics of Anticancer Agents Research (PAAR) Group and by National Institute of General Medical Sciences (National Institutes of Health, Bethesda, MD) and Grant No. U01GM61393.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. H Ezzeldin Challenges in Pharmacogenomic Testing Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 471 - 476. [Abstract] [Full Text] [PDF]

				P. Hwu, A. Y. Bedikian, and E. A. Grimm Challenges of chemosensitivity testing. Clin. Cancer Res., September 15, 2006; 12(18): 5258 - 5259. [Full Text] [PDF]

				Disparities in Cancer Care J. Oncol. Pract, September 1, 2006; 2(5): 234 - 239. [Full Text] [PDF]

				O. I. Olopade, G. Schwartsmann, N. Saijo, and C. R. Thomas Jr Disparities in Cancer Care: A Worldwide Perspective and Roadmap for Change J. Clin. Oncol., May 10, 2006; 24(14): 2135 - 2136. [Full Text] [PDF]